Development
Rapid Dose Therapeutics Corp.
DOSE
CNSX
| 11/30/2023 | 08/31/2023 | 05/31/2023 | 02/28/2023 | 11/30/2022 | |
|---|---|---|---|---|---|
| Net Income | -66.04% | 22.72% | 47.34% | 82.27% | 31.26% |
| Total Depreciation and Amortization | 34.66% | 17.28% | 18.81% | -12.93% | -31.72% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -38.18% | -62.55% | -95.68% | -96.68% | -13.54% |
| Change in Net Operating Assets | -69.25% | 52.24% | -25.91% | -27.23% | 193.16% |
| Cash from Operations | -459.89% | 54.80% | 50.10% | 15.72% | 83.95% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | 412.57% | 179.33% | 38.65% | 26.38% | -- |
| Total Debt Repaid | -443.66% | -1,269.32% | 0.00% | -604.43% | -8.32% |
| Issuance of Common Stock | -- | -- | -- | -95.59% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 387.33% | -15.15% | -41.38% | 104.43% | -60.32% |
| Foreign Exchange rate Adjustments | -- | -- | -- | 100.00% | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -100.00% | -- |
| Net Change in Cash | -459.21% | 1,371.26% | 116.38% | 101.41% | 102.29% |